Precision BioSciences (DTIL) said Monday its investigational new drug application for PBGENE-HBV in vivo gene editing program has received the US Food and Drug Administration's clearance to treat chronic hepatitis B.
The company is in final stages of US site activation to start enrolling participants in its Eliminate-B study in the country and will soon initiate phase 1 clinical activities at the Liver Center at Massachusetts General Hospital, Precision added.
The trial is already enrolling patients in Moldova, Hong Kong, and New Zealand, the company said, adding that it intends to expand the trial in the UK.
Shares of the company were up more than 7% in recent Monday premarket activity.
Price: 5.40, Change: +0.36, Percent Change: +7.14
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.